Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Revenue projections:

Revenue projections for SPARC
Revenue projections for SPARC

With SPARC's revenues projected to increase beyond last year's, the company may offer a compelling investment opportunity. If this growth aligns with positive fundamental signals, investors could view it as a sign of strong financial health and long-term profitability.

Financial Ratios:

currentRatio 0.07000
forwardPE 0.00000
debtToEquity 0.00000
earningsGrowth 0.00000
revenueGrowth 0.64200
grossMargins 0.57919
operatingMargins -1.99946
trailingEps -9.20000
forwardEps 55.40000

With a current ratio of 0.07, SPARC may not have enough cash reserves and current assets to cover its short-term debts. This suggests potential liquidity concerns, as the company may struggle to meet its immediate financial obligations.

Price projections:

Price projections for SPARC
Price projections for SPARC